FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Amarin's Free Cash Flow for the
three
months ended in Mar. 2026 was €5.5 Mil. Amarin's Revenue for the
three
months ended in Mar. 2026 was €39.0 Mil. Therefore, Amarin's FCF Margin % for the quarter that ended in Mar. 2026 was 14.16%.
The historical rank and industry rank for Amarin's FCF Margin % or its related term are showing as below:
STU:EH3'
s FCF Margin % Range Over the Past 10 Years
Min: -55.22 Med: -12.49 Max: 11.88
Current: 11.88
During the past 13 years, the highest FCF Margin % of Amarin was 11.88%. The lowest was -55.22%. And the median was -12.49%.
STU:EH3's FCF Margin % is ranked better than 74.66% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs STU:EH3: 11.88
Amarin FCF Margin % Related Terms
Amarin FCF Margin % Historical Data
* Premium members only.
The historical data trend for Amarin's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:EH3 vs SCLX, MIRA, NSRX: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Amarin's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amarin FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amarin's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Amarin's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amarin (STU:EH3) has a FCF Margin % of 14.16% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Amarin and its competitors. According to the industry distribution chart, Amarin ranks #242 out of 955 companies in the Drug Manufacturers industry, placing it in the top 25.3%.
Is Amarin's FCF Margin % too high?
Amarin's current FCF Margin % is 14.16%. The Drug Manufacturers industry median FCF Margin % is 2.51. Amarin's value of 14.16% is 464.1% above this industry median. Based on the distribution chart, Amarin ranks #242 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amarin has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Amarin's FCF Margin % compare to SCLX and MIRA?
According to the Drug Manufacturers industry distribution chart, Amarin ranks #242 out of 955 companies for FCF Margin %. This puts Amarin in the upper half of its industry. The industry median FCF Margin % is 2.51. Amarin's value of 14.16% is 464.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amarin's current FCF Margin % of 14.16% is 464.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Amarin and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amarin's current FCF Margin % is 14.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amarin stock overvalued right now?
Amarin (STU:EH3) has a current FCF Margin % of 14.16%. The stock's GF Value™ is €10.41, compared to a current price of €13.90 — trading 33.5% above its estimated fair value. The current FCF Margin % is 14.16% and 464.1% above the Drug Manufacturers industry median of 2.51. Amarin's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Amarin (STU:EH3), the current FCF Margin % is 14.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amarin (STU:EH3) Overvalued in 2026?
Based on GuruFocus' analysis, Amarin stock appears to be overvalued.
The current stock price of €13.90 is trading 33.5% above its estimated GF Value™ of €10.41.
Key valuation signals for STU:EH3:
FCF Margin %: 14.16%
GF Value™: €10.41 vs. price of €13.90 (33.5% above fair value)
Industry Position: 464.1% above the Drug Manufacturers median (#242 of 955)
No single metric tells the full story. See the STU:EH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
54GF Score
Get the complete analysis for STU:EH3
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EH3 has been successfully added to your 
